Clinical Trial
doi: 10.1212/wnl.51.2.583.
A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group
Affiliations
- PMID: 9710040
- DOI: 10.1212/wnl.51.2.583
Item in Clipboard
Clinical Trial
A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group
Neurology.
1998 Aug.
Abstract
To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.
Similar articles
-
Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.Cochrane Database Syst Rev. 2002;(3):CD002064. doi: 10.1002/14651858.CD002064. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2007 Oct 17;(4):CD002064. doi: 10.1002/14651858.CD002064.pub2 PMID: 12137643 Updated. Review.
-
Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.Cochrane Database Syst Rev. 2007 Oct 17;(4):CD002064. doi: 10.1002/14651858.CD002064.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2012 Nov 14;11:CD002064. doi: 10.1002/14651858.CD002064.pub3 PMID: 17943766 Updated. Review.
-
Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease.Cochrane Database Syst Rev. 2012 Nov 14;11:CD002064. doi: 10.1002/14651858.CD002064.pub3. Cochrane Database Syst Rev. 2012. PMID: 23152212 Review.
-
Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.Neurology. 1997 Dec;49(6):1621-30. doi: 10.1212/wnl.49.6.1621. Neurology. 1997. PMID: 9409357 Clinical Trial.
-
Recombinant human insulin-like growth factor-I in ALS: description of a double-blind, placebo-controlled study. North American ALS/IGF-I Study Group.Neurology. 1996 Oct;47(4 Suppl 2):S93-4; discussion S94-5. doi: 10.1212/wnl.47.4_suppl_2.93s. Neurology. 1996. PMID: 8858058 Clinical Trial. No abstract available.
Cited by
-
Enhanced insulin signalling ameliorates C9orf72 hexanucleotide repeat expansion toxicity in Drosophila.Elife. 2021 Mar 19;10:e58565. doi: 10.7554/eLife.58565. Elife. 2021. PMID: 33739284 Free PMC article.
-
Human conditions of insulin-like growth factor-I (IGF-I) deficiency.J Transl Med. 2012 Nov 14;10:224. doi: 10.1186/1479-5876-10-224. J Transl Med. 2012. PMID: 23148873 Free PMC article. Review.
-
Repetitive acute intermittent hypoxia increases expression of proteins associated with plasticity in the phrenic motor nucleus.Exp Neurol. 2012 Sep;237(1):103-15. doi: 10.1016/j.expneurol.2012.05.020. Epub 2012 Jun 21. Exp Neurol. 2012. PMID: 22704858 Free PMC article.
-
The lack of effect of specific overexpression of IGF-1 in the central nervous system or skeletal muscle on pathophysiology in the G93A SOD-1 mouse model of ALS.Exp Neurol. 2007 Sep;207(1):52-63. doi: 10.1016/j.expneurol.2007.05.016. Epub 2007 Jun 2. Exp Neurol. 2007. PMID: 17597610 Free PMC article.
-
Therapeutic Effects of Combination of Nebivolol and Donepezil: Targeting Multifactorial Mechanisms in ALS.Neurotherapeutics. 2023 Oct;20(6):1779-1795. doi: 10.1007/s13311-023-01444-7. Epub 2023 Oct 2. Neurotherapeutics. 2023. PMID: 37782409 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
